We aimed to assess how p53 induced upregulation of annexin/S100A would affect the following clinical outcomes: Relapse Free Survival (RFS), Distant Metastasis Free Survival (DMFS), and Overall Survival (OS), both in untreated and treated ER+ (luminal A) breast cancer patients. This evidence concerns the gene TP53 and breast carcinoma.